Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Wharton

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Handbook of Experimental Pharmacology|October 5, 2013
Pulmonary hypertension: biomarkersChristopher J Rhodes, John Wharton, Martin R Wilkins
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 21, 2004
Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblastsSassan Hafizi, John Wharton, Adrian H Chester, et al.
Trends in Cardiovascular Medicine|August 6, 2010
Endothelial progenitor cells in pulmonary arterial hypertensionGerhard-Paul Diller, Thomas Thum, Martin R Wilkins, et al.
Respiratory Research|October 18, 2011
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cellsOmar F Ali, Ellena J Growcott, Ghazwan S Butrous, et al.
Clinical Science (London, England : 1979)|March 1, 2002
Recent insights into the pathogenesis and therapeutics of pulmonary hypertensionJulian W Strange, John Wharton, Peter G Phillips, et al.
Circulation|May 5, 2016
Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2αZhiyu Dai, Ming Li, John Wharton, et al.
Expert Opinion on Investigational Drugs|May 16, 2007
Emerging therapies for pulmonary arterial hypertensionOmar Ali, John Wharton, John Simon Russell Gibbs, et al.
British Journal of Pharmacology|March 24, 2020
The application of 'omics' to pulmonary arterial hypertensionLars Harbaum, Christopher J Rhodes, Pablo Otero-Núñez, et al.
Journal of Biomedical Science|January 21, 2016
Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesisDaria Belik, Hilda Tsang, John Wharton, et al.
Circulation|June 11, 2003
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertensionA Sebkhi, Julian W Strange, Steven C Phillips, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Handbook of Experimental Pharmacology|October 5, 2013
Pulmonary hypertension: biomarkersChristopher J Rhodes, John Wharton, Martin R Wilkins
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 21, 2004
Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblastsSassan Hafizi, John Wharton, Adrian H Chester, et al.
Trends in Cardiovascular Medicine|August 6, 2010
Endothelial progenitor cells in pulmonary arterial hypertensionGerhard-Paul Diller, Thomas Thum, Martin R Wilkins, et al.
Respiratory Research|October 18, 2011
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cellsOmar F Ali, Ellena J Growcott, Ghazwan S Butrous, et al.
Clinical Science (London, England : 1979)|March 1, 2002
Recent insights into the pathogenesis and therapeutics of pulmonary hypertensionJulian W Strange, John Wharton, Peter G Phillips, et al.
Circulation|May 5, 2016
Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2αZhiyu Dai, Ming Li, John Wharton, et al.
Expert Opinion on Investigational Drugs|May 16, 2007
Emerging therapies for pulmonary arterial hypertensionOmar Ali, John Wharton, John Simon Russell Gibbs, et al.
British Journal of Pharmacology|March 24, 2020
The application of 'omics' to pulmonary arterial hypertensionLars Harbaum, Christopher J Rhodes, Pablo Otero-Núñez, et al.
Journal of Biomedical Science|January 21, 2016
Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesisDaria Belik, Hilda Tsang, John Wharton, et al.
Circulation|June 11, 2003
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertensionA Sebkhi, Julian W Strange, Steven C Phillips, et al.
Pageof 7